Gerresheimer’s Two-Faced Market: Insider Buying and a 41% Rally Meet a Missing Audit

Activist investor pours €10M as Gerresheimer stock surges 41% on GLP-1 demand, yet faces SDAX ejection, audit delays, and deep distrust.

A curious split has taken hold of Gerresheimer. In one corner, the packaging group is caught in a maelstrom of regulatory investigations, an overdue audited balance sheet, and the humiliating ejection from the SDAX. In the other, the stock has just ripped 41.1% higher in a single month, propelled by the insatiable demand for GLP-1 weight-loss drugs. And right in the middle, a major activist investor has quietly poured nearly €10 million into the crumbling share price.

Active Ownership Capital, the investment firm known for shaking up corporate boards, executed several tranches of purchases through its vehicle AOC Gecko during early May. The buying spree took its stake well past the 15% threshold. The market largely shrugged: the shares closed on Friday at €24.92, still nursing a weekly loss of almost 9%. Over twelve months, the stock has haemorrhaged about 60% of its value. Annualised volatility sits at an extreme 69%, and the 200-day moving average has once again been breached to the downside.

The disconnect between the insider buying and the broader market reaction underscores the deep distrust hanging over Gerresheimer. The root cause is the failure to deliver a certified annual report on time. Unauthorised booking practices – involving invoicing customers before delivery – forced the company’s exit from the SDAX in April. The fallout has been relentless: the audit oversight body APAS is investigating KPMG’s work, while BaFin has turned its attention to misstated leasing liabilities of roughly €65 million and erroneous capitalisation of development costs.

Lenders have given management some breathing room. Banks and Schuldschein investors extended the deadline for the audited accounts to the end of September 2026 and temporarily suspended key leverage covenants. To lighten the balance sheet, the board is pushing ahead with the sale of the US subsidiary Centor, a maker of pharmacy market packaging, which should close before year-end. The company still targets revenue of up to €2.4 billion for 2026. The next hard catalysts come in June, when management promises both the certified annual report and first-quarter figures, followed by the half-year numbers on July 14.

Yet the very same crisis has masked a powerful growth story that explains the recent share surge. Gerresheimer is a critical supplier of glass vials and syringe systems for GLP-1 drugs used to treat obesity and diabetes. The global rollout of these therapies is creating enormous demand, and the extreme regulatory barriers to entry mean competitors cannot easily step in. Massive capacity investments for biologics packaging are now driving a fundamental revaluation. The 41.1% monthly gain – the strongest in the entire MDAX – appears to be a belated recognition of that long-term opportunity.

But technical and fundamental caution is warranted. The stock remains roughly 60% below its 52-week high and is still down about 10% year to date. The relative strength index stands at 28.1, signalling an oversold condition – a paradox after such a sharp monthly rally, but explained by the preceding weekly slide. Whether operating margins will expand proportionally with volume remains to be seen in the coming quarterly reports. The leap in price has mostly corrected a portion of a longer descent rather than signalling a clean breakout.

For now, Gerresheimer embodies two contradictory narratives: a deep accounting quagmire that erodes trust, and a booming product cycle that could transform its earnings power. The insider stakebuild of nearly €10 million suggests that at least one major shareholder believes the latter will eventually outweigh the former. The next few months will test that conviction with the hardest data yet – audited numbers, regulatory outcomes, and Centor proceeds. Until then, the stock is caught between a 41% rush and a missing signature.